SYK inhibitors show RR of 10.26 for durable platelet response in immune thrombocytopenia
New IgG-Pathway Inhibitors Show Promise for Immune Thrombocytopenia
This meta-analysis of randomized controlled trials evaluates IgG-pathway inhibitors, including SYK, FcRn, and BTK inhibitors, for immune thr…
New types of medications called IgG-pathway inhibitors may offer more durable platelet responses for adults with immune thrombocytopenia.
Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options
New Hope for Chronic Hives Targets Specific Triggers
This narrative review examines chronic inducible urticaria (CIndU), focusing on H1-antihistamines, omalizumab, anti-KIT biologics, and BTK i…
New medicines are being built to fix the exact reason your hives appear, moving away from a one-size-fits-all approach.